Technology
Zepp Health Corporation Reports Fourth Quarter and Full Year 2024 Unaudited Financial Results
Published
1 year agoon
By
MILPITAS, Calif., March 26, 2025 /PRNewswire/ — Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today announced its unaudited financial results for the fourth quarter of 2024.
Fourth Quarter 2024 Financial and Operating Highlights:
Revenue reached US$59.5 million representing a 40.2% of quarter over quarter increase, out of which our Amazfit-branded products grew by 43.4% quarter-over-quarter.Gross margin was 36.8% compared with 34.7% in the same period last year.Adjusted operating loss[1] was US$7.4 million, which was the lowest level in 2024.
Full Year 2024 Financial and Operating Highlights:
Gross margin was 38.5% compared with 26.2% in the full year of 2023.Adjusted operating expenses[2] was US$110.4 million, compared with US$111.7 million in the full year of 2023.
[1] Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Please refer to the section titled “Reconciliation of GAAP and non-GAAP results”
[2] Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Please refer to the section titled “Reconciliation of GAAP and non-GAAP results”
Mr. Wang ‘Wayne’ Huang, Chairman and CEO of Zepp, commented, “In the fourth quarter of 2024, despite macroeconomic challenges and supply bottlenecks, we kept transitioning to a higher-margin, enhanced brand power model. Our fourth quarter of 2024 sales rose 40% quarter-over-quarter, in line with guidance. In 2024, our gross margin was 38.5%, up from 26.2% in 2023. We ended the year with US$111 million in cash, enabling investment and market response. The T-Rex 3 became a dark horse in the outdoor and sports watch market. Six months after launch, user activations rose steadily, with plenty of positive feedback from users and KOLs. We’re confident it’ll keep rising, driving Amazfit sales with good margins and bringing us closer to near-term profitability.”
Wayne added, “In branding, we’ve been beefing up the Amazfit athletes team. Five-time Olympic medallist Gabby Thomas and Italian tennis star Jasmine Polini recently joined as Athlete Ambassadors. We’re also deepening the HYROX collaboration and will launch more powerful HYROX products and features. These partnerships have boosted confidence among major offline key account partners in the US and Europe, who have allocated us more display space to replace competitors’ counters, which will fuel growth in the second half of the year. “
Wayne concluded: “Leveraging Active 2 and Bip 6 series, we’re expanding market share, growing the entry-level user base, and enhancing brand influence in the value-for-money segment, especially in emerging markets. Since its launch in the first quarter, Active 2 has gained strong momentum in Europe and the U.S., with excellent media reviews calling it the best smartwatch at the $100 price point, and very positive user feedback.
On the technology side, we’re advancing Zepp OS with OpenAI 4.5 integration. In nutrition tracking, our food logging feature by picture and video analytics within the Zepp App is now available in Europe and North America, receiving increasingly strong user adoption. To accelerate large-scale deployment of both Zepp OS and food logging capabilities, we’re exploring DeepSeek’s power to significantly reduce processing costs. With a robust roadmap and an integrated ecosystem, we’ve never been more confident about our future.”
Zepp Health’s CFO, Mr. Leon Deng, said, “The fourth quarter of 2024 revenue grew 40.2% quarter-over-quarter due to T-Rex 3 launch, but declined 28.3% YoY due to product structure changes and macro headwinds. The gross margin was 36.8% in the fourth quarter 2024, up from 34.7% in the fourth quarter of 2023 and grew from 26.2% in the full year of 2023 to 38.5% in the full year of 2024, helped by better product mix and brand awareness. Operating costs were in check and aligned with guidance, achieving the highest quarterly adjusted EBIT[3] in 2024, moving towards break even. The fourth quarter of 2024 GAAP loss was US$36.9 million with various provisions, which are non-cash and one-off in nature.
As of December 31, 2024, the company had US$111 million in cash, down from US$140 million as of Dec 31, 2023, mainly due to lower operating profit offset by better working capital management. Inventory balance stood at US$56.8 million on Dec 31, 2024, it was the lowest since 2018. By February 2025, the company has successfully refinanced majority of its short-term debts maturing in 2025 into long-term debt instruments with a low coupon rate. Following this adjustment, long-term debt accounts for around 75% of the company’s overall debt structure. Since the first quarter of 2023, US$56.3 million of the total debt had been retired and the capital structure would be further optimized as operating cash flow strengthened.
We are pleased to see that revenue resumed an upward trend in the first quarter of 2025, boosting confidence for 2025. The share repurchase program would continue in 2025, showing faith in Zepp Health’s long-term potential and commitment to shareholder value.”
[3] Adjusted EBIT is a non-GAAP financial measure, which is defined as net loss, excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/ expense, and (vii) interest income and interest expense.
Fourth Quarter 2024 Financial Results
Revenues
Revenues for the fourth quarter of 2024 reached US$59.5 million, a decrease by 28.3% from the fourth quarter of 2023. The decrease was primarily due to the decrease in the sales of Xiaomi wearable products, as well as the decrease in sales of Amazfit-branded products, due to different new product launch timing and product mix, with fewer SKUs currently on sale compared to 2023. Also, supply was still somewhat constrained by the production capacity for T-Rex 3 in the fourth quarter. However, compared with the third quarter of 2024, revenue of Amazfit-branded products increased by 43.4%, which is the highest quarter-over-quarter increase in 2024, the increase was primarily driven by the positive market reception of our recent launches, especially the newly introduced Amazfit T-Rex 3, and our core products such as Balance, Active, have seen continued popularity and growing demand.
Gross Margin
Gross margin in the fourth quarter of 2024 was 36.8%, compared to 34.7% in the same period of 2023. Higher gross margin of self-branded products was primarily driven by the product mix, especially higher gross margin of T-Rex 3.We expect the positive gross margin trend to continue into 2025 with the new product launches, such as Amazfit Active 2 and Amazfit Bip 6.
Research and Development Expenses
Research and development expenses in the fourth quarter of 2024 were US$11.1 million, a decrease by 0.6% year-over-year. The decrease was as a result of our refined research and development approaches, as we consistently evaluated resource efficiency to ensure maximum return on investment and productivity. We are committed to investing in new technologies and AI to maintain our competitive edge against our peers.
Selling and Marketing Expenses
Selling and marketing expenses in the fourth quarter of 2024 were US$13.3 million, an increase by 10.6% year-over-year.
The increase was primarily due to the peak season for promotional campaigns to build brand recognition and drive sales growth. At the same time, we consistently pushed on retail profitability and channel mix improvement, which included meticulous refinement of our retail channels and strategic staffing arrangements across sales regions. We are committed to investing efficiently in marketing and branding to ensure our sustainable growth.
General and Administrative Expenses
General and administrative expenses were US$6.6 million in the fourth quarter of 2024, an increase by 28.5% year-over-year. The increase was largely attributable to provision for bad debt and foreign exchange rate fluctuations.
Operating Expenses
Total operating expenses for the fourth quarter of 2024 were US$30.9 million, an increase by 9.4% year-over-year. Adjusted operating expenses, which exclude share-based compensation and amortization of intangible assets resulting from acquisitions and business cooperation agreements, were US$29.3 million. The increase was primarily due to the launch of various marketing campaigns to build brand recognition and drive sales growth and provision for bad debt. We will maintain our cost-conscious approach in the upcoming quarters. Concurrently, we remain committed to investing in R&D and marketing activities to ensure our long-term competitiveness.
Operating Income/(Loss)
Operating loss for the fourth quarter of 2024 was US$8.9 million, compared to operating income of US$0.6 million for the fourth quarter of 2023. Adjusted operating loss for the fourth quarter of 2024 was US$7.4 million, compared to adjusted operating income of US$3.0 million for the fourth quarter of 2023. The loss was mainly due to lower sales volume, which resulted in an inability to fully cover operating expenses. The adjusted operating loss was the narrowest among four quarters in 2024.
Net Income/(Loss)
Net loss attributable to Zepp Health Corporation for the fourth quarter of 2024 was US$36.9 million, compared to net loss of US$1.3 million in the fourth quarter of 2023, which included operating loss of US$8.9 million, income tax impacts of US$13.6 million (primarily result from valuation allowance for deferred tax assets) and net investment results of US$12.9 million (including impairment loss from investments, loss from equity method investments, loss from fair value change of long-term investment), both are non-recurring and non-cash in nature.
Adjusted net loss attributable to Zepp Health Corporation[4] was US$22.5 million, compared to adjusted net loss of US$0.5 million in the fourth quarter of 2023. Adjusted EBIT in the fourth quarter of 2024 was loss of US$8.2 million, it represents the narrowest loss among all four quarters in 2024.
[4] Adjusted net income/(loss) attributable to Zepp Health Corporation represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments. See “Reconciliation of GAAP and non-GAAP results” at the end of this press release.
Liquidity and Capital Resources
As of December 31, 2024, the Company had cash and cash equivalents and restricted cash of US$111 million, compared with US$140 million of cash balance as of December 31, 2023, the result is driven by US$56.7 million adjusted net loss for the year of 2024, offset by US$27.7 million tighter working capital management. The decrease of cash balance was mainly the result of the operating activities. This cash position provides ample runway for the Company to invest and seize potential market opportunities.
The Company continued to manage its working capital and inventory efficiently and recorded inventory of US$56.8 million as of December 31, 2024, it was the lowest level since 2018. We will continue to manage working capital tightly.
By February 2025, we have successfully refinanced majority of our short-term debts maturing in 2025 to a multi-year long term debt maturing in 2027 and beyond with a lower interest rate. Starting the first quarter of 2023, we have initiated the retirement of our short/long-term debt portfolio. Since then, and including the fourth quarter of 2024 we have successfully retired US$56.3 million of debt. As our operating cash flow continues to strengthen, we will continue to optimize the capital structure for the company.
Shares Outstanding
As of December 31, 2024, the Company had a total of 232.0 million ordinary shares outstanding, representing the equivalent of 14.5 million ADSs assuming the conversion of all ordinary shares into ADSs.
Share Repurchase Program Update
The Company announced in its third quarter 2021 earnings release that the board had authorized a share repurchase program of up to US$20 million through November 2022. On November 21, 2022, the board authorized a 12-month extension of the Company’s share repurchase program. On November 20, 2023, the board further authorized the Company to extend its share repurchase program for another 12 months. On November 18, 2024, the board further authorized the Company to extend its share repurchase program for another 24 months. Pursuant to the extended share repurchase program, the Company may repurchase its shares in the form of ADSs and/or ordinary shares through November 2026 with an aggregate value equal to the remaining balance under the share repurchase program. As of December 31, 2024, the Company had used US$15.0 million to repurchase approximately 1.9 million ADSs. The Company expects to fund the repurchases under the extended share repurchase program out of its existing cash balance.
Full Year 2024
Revenues
Total revenues of 2024 reached US$182.6 million, a decrease of 48.3% from the full year of 2023. The decrease in total revenues mainly resulted from an 88.0% decline in the sales of Xiaomi wearable products. In 2024, Amazfit-branded products accounted for 94.0% of our total revenues, compared with 73.9% in 2023. Sales of our Amazfit-branded product decreased by 34.2% as compared with 2023. This was mainly because in 2024 we only have one new product (Amazfit T-Rex 3), which was launched by the end of third quarter.
Gross Margin
Gross margin in the full year 2024 was 38.5%, 12.3 percentage points higher than 26.2% in the full year of 2023. The higher gross margin of Amazfit-branded products was very much driven by the product mix, especially higher gross margin of newly launched products.
Research and Development Expenses
Research and development expenses for the full year 2024 were US$46.2 million, a decrease of 10.4% year-over-year. The decrease was as a result of our refined research and development approaches, as we consistently evaluated resource efficiency to ensure maximum return on investment and productivity. We are committed to investing in new technologies and AI to maintain our competitive edge against our peers.
Selling and Marketing Expenses
Selling and marketing expenses for the full year 2024 were US$46.5 million, an increase of 4.4% year-over-year.
The increase was primarily due to the launch of various marketing campaigns for our products, as well as the expansion of our Amazfit Athletes team by partnering with renowned athletes to build brand recognition. At the same time, we consistently pushed on retail profitability and channel mix improvement, which included meticulous refinement of our retail channels and strategic staffing arrangements across sales regions. We are committed to investing efficiently in marketing and branding to ensure our sustainable growth.
General and Administrative Expenses
General and administrative expenses were US$24.9 million in the full year 2024, a decrease of 7.2% year-over-year. The decrease was largely attributable to strict administrative expense control.
Operating Expenses
Total operating expenses for the full year 2024 were US$117.5 million, a decrease of 4.3% year-over-year. Adjusted operating expenses, which exclude share-based compensation expenses and amortization of intangible assets resulting from acquisitions and business cooperation agreements, were US$110.4 million, compared with US$111.7 million for the full year 2023. We plan to continue our focus on cost efficiency in the upcoming year. At the same time, we are dedicated to invest in R&D and marketing efforts, which are essential for maintaining our competitive edge over the long term.
Net Income/(Loss)
Net loss attributable to Zepp Health Corporation for the full year of 2024 was US$75.7 million, compared with US$31.0 million in net loss in 2023. The adjusted net loss attributable to Zepp Health Corporation was US$56.7 million, compared with the adjusted net loss of US$21.3 million for the same period of 2023. The adjusted EBIT for the full year of 2024 was loss of US$40.9 million, compared with loss of US$19.8 million in 2023. In the full year of 2024, the Company recorded income tax impacts of US$13.7 million (primarily resulting from valuation allowance for deferred tax assets) and net investment results of US$12.3 million (including impairment loss from investments, loss from equity method investments, and gain from fair value change of long-term investment), both are non-recurring and non-cash in nature.
Outlook
For the first quarter of 2025, the Company’s management currently expects net revenues to be between US$40 million and US$45 million, representing 14% to 29% growth for revenue of Amazfit-branded products compared with first quarter of 2024.
This outlook is based on current market conditions and reflects the Company’s current and preliminary estimates of market, operating conditions and customer demand, which are all subject to change.
Conference Call
The Company’s management team will hold a conference call at 7:00 p.m. Eastern Time on Wednesday, March 26, 2025 to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:
US (Toll Free):
+1-888-346-8982
International:
+1-412-902-4272
Mainland China (Toll Free):
400-120-1203
Hong Kong (Toll Free):
800-905-945
Hong Kong:
+852-3018-4992
Participants should dial in at least 10 minutes before the scheduled start time and ask to be connected to the call for “Zepp Health Corporation”.
Additionally, a live and archived webcast of the conference call will be available at http://ir.zepp.com.
A telephone replay will be available one hour after the call until April 2, 2025 by dialing:
US Toll Free:
+1-877-344-7529
International:
+1-412-317-0088
Replay Passcode:
1239487
About Zepp Health Corporation
Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable and health technology leader, empowering users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity and Zepp Aura. Powered by its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors and data algorithms, Zepp delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp has shipped over 200 million units, and its products are available in more than 90 countries and regions. Founded in 2013 as Huami Corp., the Company changed its name to Zepp Health Corporation in February 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. Zepp has team members and offices across globe, especially in Europe and USA regions.
Use of Non-GAAP Measures
We use adjusted net income/(loss), a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted operating expenses represent operating expenses excluding (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted operating income/(loss) represents operating income/(loss) excluding: (i) share-based compensation expenses and (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements. Adjusted EBIT represents net income/(loss) excluding (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, (vi) income tax (benefit)/expense, and (vii) interest income and interest expense. Adjusted net income/(loss) attributable to Zepp Health Corporation is a non-GAAP measure, which excludes (i) share-based compensation expenses, (ii) amortization of intangible assets resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment, (iv) impairment loss from long-term investments, (v) income/(loss) from equity method investments, and (vi) tax effects of the above non-GAAP adjustments, and is used as the numerator in computation of adjusted net income/(loss) per share and per ADS attributable to Zepp Health Corporation.
We believe that adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income/(loss) and net income/(loss) attributable to Zepp Health Corporation. We believe adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.
Adjusted EBIT and adjusted net income/(loss) attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income/(loss), basic and diluted net income/(loss) per share and per ADS attributable to Zepp Health Corporation or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted EBIT and adjusted net income/(loss) attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company’s Amazfit-branded products; the Company’s growth strategies; trends and competition in global wearable technology market; changes in the Company’s revenues and certain cost or expense accounting policies; governmental policies relating to the Company’s industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company’s filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com
Piacente Financial Communications
Tel: +86-10-6508-0677
Email: zepp@tpg-ir.com
Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
As of December 31,
As of December 31,
2023
2024
US$
US$
Assets
Current assets:
Cash and cash equivalents
133,669
91,069
Restricted cash
6,800
19,666
Accounts receivable, net
60,727
62,965
Amounts due from related parties
8,605
2,663
Inventories, net
84,887
56,789
Short-term investments
5,153
997
Prepaid expenses and other current assets
16,891
17,415
Total current assets
316,732
251,564
Property, plant and equipment, net
8,929
6,898
Intangible asset, net
9,868
7,091
Goodwill
9,581
9,581
Long-term investments
238,540
225,910
Deferred tax assets
32,401
17,465
Amount due from related parties, non-current
2,951
2,019
Other non-current assets
9,698
4,607
Operating lease right-of-use assets
6,819
3,458
Total assets
635,519
528,593
Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS – CONTINUED
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
As of December 31,
As of December 31,
2023
2024
US$
US$
Liabilities
Current liabilities:
Accounts payable
37,286
51,077
Advance from customers
233
197
Amount due to related parties
3,475
2,477
Accrued expenses and other current liabilities
44,450
37,576
Income tax payables
986
508
Notes payable
66,991
61,679
Short-term bank borrowings
1,690
41,853
Total current liabilities
155,111
195,367
Deferred tax liabilities
4,169
3,117
Long-term borrowings
120,020
75,241
Other non-current liabilities
270
133
Non-current operating lease liabilities
3,197
2,007
Total liabilities
282,767
275,865
Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS – CONTINUED
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
As of December 31,
As of December 31,
2023
2024
US$
US$
Equity
Ordinary shares
26
26
Additional paid-in capital
273,386
278,116
Treasury stock
(12,874)
(14,993)
Accumulated retained earnings
104,351
28,618
Accumulated other comprehensive loss
(14,008)
(40,178)
Total Zepp Health Corporation shareholders’ equity
350,881
251,589
Noncontrolling interest
1,871
1,139
Total equity
352,752
252,728
Total liabilities and equity
635,519
528,593
Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
For the Three Months Ended December 31,
2023
2024
US$
US$
Revenues
83,007
59,542
Cost of revenues
(54,173)
(37,613)
Gross profit
28,834
21,929
Operating expenses:
Selling and marketing
(11,984)
(13,251)
General and administrative
(5,100)
(6,555)
Research and development
(11,124)
(11,061)
Total operating expenses
(28,208)
(30,867)
Operating income/(loss)
626
(8,938)
Other income and expenses:
Interest income
825
771
Interest expense
(1,438)
(1,447)
Other income/(expense), net
116
(767)
(Loss)/gain from fair value change of long-term investments
(709)
33
Impairment loss from investments
(313)
(10,129)
Investment loss
(44)
–
Loss before income tax and loss from equity method investments
(937)
(20,477)
Income tax expenses
(2,775)
(13,574)
Loss before income/(loss) from equity method investments
(3,712)
(34,051)
Net income/(loss) from equity method investments
2,448
(2,850)
Net loss
(1,264)
(36,901)
Less: Net income/(loss) attributable to noncontrolling interest
15
(25)
Net loss attributable to Zepp Health Corporation
(1,279)
(36,876)
Net loss per share attributable to Zepp Health Corporation
Basic loss per ordinary share
(0.01)
(0.14)
Diluted loss per ordinary share
(0.01)
(0.14)
Net loss per ADS (16 ordinary shares equal to 1 ADS)
ADS – basic
(0.08)
(2.29)
ADS – diluted
(0.08)
(2.29)
Weighted average number of shares used in computing net loss per
share
Ordinary share – basic
241,521,944
257,216,039
Ordinary share – diluted
241,521,944
257,216,039
Zepp Health Corporation
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
For the Three Months Ended December 31,
2023
2024
US$
US$
Total operating expenses
(28,208)
(30,867)
Share-based compensation expenses
1,779
951
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
566
567
Total adjusted operating expenses
(25,863)
(29,349)
Operating income/(loss)
626
(8,938)
Share-based compensation expenses
1,779
951
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
566
567
Adjusted operating income/(loss)
2,971
(7,420)
Net loss
(1,264)
(36,901)
Share-based compensation expenses
1,779
951
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
566
567
Loss/(gain) from fair value change of long-term
investments
709
(33)
Impairment loss from investments
313
10,129
(Income)/loss from equity method investments
(2,448)
2,850
Income tax expenses
2,775
13,574
Interest income
(825)
(771)
Interest expense
1,438
1,447
Adjusted EBIT
3,043
(8,187)
Net loss attributable to Zepp Health Corporation
(1,279)
(36,876)
Share-based compensation expenses
1,779
951
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
566
567
Loss/(gain) from fair value change of long-term
investments
709
(33)
Impairment loss from investments
313
10,129
(Income)/loss from equity method investments
(2,448)
2,850
Tax effects on non-GAAP adjustments
(91)
(91)
Adjusted net loss attributable to Zepp Health
Corporation
(451)
(22,503)
Adjusted net loss per share attributable to
Zepp Health Corporation
Adjusted basic loss per ordinary share
(0.002)
(0.09)
Adjusted diluted loss per ordinary share[5]
(0.002)
(0.09)
Adjusted net loss per ADS (16 ordinary shares equal to
1 ADS)
ADS – basic
(0.03)
(1.40)
ADS – diluted
(0.03)
(1.40)
Weighted average number of shares used in computing
adjusted net loss per share
Ordinary share – basic
241,521,944
257,216,039
Ordinary share – diluted
241,521,944
257,216,039
Share-based compensation expenses included
are follows:
Selling and marketing
140
94
General and administrative
1,142
433
Research and development
497
424
Total
1,779
951
[5] Adjusted diluted net income/(loss) is the abbreviation of adjusted net (loss)/income attributable to Zepp Health Corporation,
which is a non-GAAP measure and excludes (i) share-based compensation expenses, (ii) amortization of intangible assets
resulting from acquisitions and business cooperation agreements, (iii) gain/(loss) from fair value change of long-term investment,
(iv) impairment loss from long-term investments, and (v) income/(loss) from equity method investments, and (vi) tax effects of
the above non-GAAP adjustments, and is used as the numerator in computation of adjusted basic and diluted net loss per ADS
attributable to Zepp Health Corporation.
Zepp Health Corporation
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
Years Ended December 31,
2023
2024
US$
US$
Revenues
352,860
182,603
Cost of revenues
(260,502)
(112,369)
Gross profit
92,358
70,234
Operating expenses:
Selling and marketing
(44,527)
(46,471)
General and administrative
(26,778)
(24,854)
Research and development
(51,503)
(46,159)
Total operating expenses
(122,808)
(117,484)
Operating loss
(30,450)
(47,250)
Other income and expenses:
Interest income
3,089
3,672
Interest expense
(6,752)
(5,552)
Other expense, net
(525)
(656)
Gain from fair value change of long-term investments
213
2,011
Impairment loss from investments
(313)
(10,129)
Investment income
109
–
Loss before income tax and income/(loss) from equity method
investments
(34,629)
(57,904)
Income tax benefits/(expenses)
2,430
(13,693)
Loss before income/(loss) from equity method investments
(32,199)
(71,597)
Net income/(loss) from equity method investments
1,113
(4,211)
Net loss
(31,086)
(75,808)
Less: Net loss attributable to noncontrolling interest
(66)
(75)
Net loss attributable to Zepp Health Corporation
(31,020)
(75,733)
Net loss per share attributable to Zepp Health Corporation
Basic loss per ordinary share
(0.13)
(0.29)
Diluted loss per ordinary share
(0.13)
(0.29)
Net loss per ADS (16 ordinary shares equal to 1 ADS)
ADS – basic
(2.04)
(4.68)
ADS – diluted
(2.04)
(4.68)
Weighted average number of shares used in computing net loss per
share
Ordinary share – basic
243,135,964
258,876,120
Ordinary share – diluted
243,135,964
258,876,120
Zepp Health Corporation
Reconciliation of GAAP and Non-GAAP Results
(Amounts in thousands of U.S. dollars (“US$”)
except for number of shares and per share data, or otherwise noted)
Years Ended December 31,
2023
2024
US$
US$
Total operating expenses
(122,808)
(117,484)
Share-based compensation expenses
8,792
4,778
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
2,285
2,267
Total adjusted operating expenses
(111,731)
(110,439)
Operating loss
(30,450)
(47,250)
Share-based compensation expenses
8,792
4,778
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
2,285
2,267
Adjusted operating loss
(19,373)
(40,205)
Net loss
(31,086)
(75,808)
Share-based compensation expenses
8,792
4,778
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
2,285
2,267
Gain from fair value change of long-term investments
(213)
(2,011)
Impairment loss from investments
313
10,129
(Income)/loss from equity method investments
(1,113)
4,211
Income tax (benefits)/expenses
(2,430)
13,693
Interest income
(3,089)
(3,672)
Interest expense
6,752
5,552
Adjusted EBIT
(19,789)
(40,861)
Net loss attributable to Zepp Health Corporation
(31,020)
(75,733)
Share-based compensation expenses
8,792
4,778
Amortization of intangible assets resulting from
acquisitions and business cooperation agreements
2,285
2,267
Gain from fair value change of long-term investments
(213)
(2,011)
Impairment loss from investments
313
10,129
(Income)/loss from equity method investments
(1,113)
4,211
Tax effects on non-GAAP adjustments
(368)
(365)
Adjusted net loss attributable to Zepp Health
Corporation
(21,324)
(56,724)
Adjusted net loss per share attributable to
Zepp Health Corporation
Adjusted basic loss per ordinary share
(0.09)
(0.22)
Adjusted diluted loss per ordinary share
(0.09)
(0.22)
Adjusted net loss per ADS (16 ordinary shares equal to
1 ADS)
ADS – basic
(1.40)
(3.51)
ADS – diluted
(1.40)
(3.51)
Weighted average number of shares used in computing
adjusted net loss per share
Ordinary share – basic
243,135,964
258,876,120
Ordinary share – diluted
243,135,964
258,876,120
Share-based compensation expenses included
are follows:
Selling and marketing
637
462
General and administrative
4,296
2,245
Research and development
3,859
2,071
Total
8,792
4,778
View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-fourth-quarter-and-full-year-2024-unaudited-financial-results-302412131.html
SOURCE Zepp Health Corp.
You may like
Technology
Reach Showcases Full-Stack Product Portfolio for AI Vehicle Intelligent Evolution at Auto China 2026
Published
1 hour agoon
May 1, 2026By
BEIJING, April 30, 2026 /PRNewswire/ — At Auto China 2026, Reach officially unveiled its full-stack product portfolio designed to accelerate the intelligent evolution of AI vehicles. Industry leaders and experts, along with executives and representatives from Honda, Toyota, FAW, Geely, GAC, Dongfeng Voyah, FAW Jiefang, BMW, Volkswagen CARIAD, Chery, Nissan, Mazda, Hitachi Astemo, Bosch, UAES, ZTE Microelectronics and other global OEMs and industry partners, visited the booth for in-depth discussions on the future of AI-powered mobility and intelligent vehicle evolution.
At the show, Reach demonstrated how AI vehicles are moving from “responding to commands” to “understanding intent and proactively serving users.” Human-vehicle interaction is evolving from isolated smart functions to integrated intelligent experiences, creating a new vision for future mobility.
Supporting this transformation is Reach’s full-stack portfolio covering five key areas: AI Vehicle Neural Foundation, Emotional Cognition, Intelligent Driving Brain, Vehicle-Cloud Computational Brain, and Energy Heart.
At the core is NeuSAR OS, the digital foundation for AI vehicles. Backed by over 10 million production deployments, it provides secure, reliable, and scalable support for AI applications, enabling unified management of vehicle-wide capabilities, cross-domain resources, and AI Agents while improving development efficiency by 30%–50%.
Cloud OS introduces a vehicle-cloud collaborative computing architecture that allows flexible scheduling between onboard small models and cloud-based large models, reducing hardware dependency and optimizing computing costs.
For intelligent driving, Reach’s full-stack AI solution and fifth-generation architecture NeuAUTO support faster mass production across passenger and commercial vehicles through unified software architecture and end-to-end AI models.
Reach AI Data-driven EV power system enables proactive battery health management and energy optimization. It also introduced AI-powered automated testing systems to improve testing efficiency and coverage.
Reach also launched its lifecycle-wide AI Agent solution, built on a full-domain data platform and intelligent systems for planning, after-sales, and operations, it supports product planning, price forecasting, safety monitoring, and customer operations across the full vehicle lifecycle.
As AI vehicles evolve toward full-system intelligence, system-level capability building and ecosystem collaboration are becoming the key to competitiveness. Reach is collaborating with global OEMs, Tier 1 suppliers, and semiconductor partners to accelerate large-scale industrial deployment.
Looking ahead, Reach continues advancing its full-stack portfolio through stronger innovation and deeper ecosystem collaboration, enabling vehicles evolve into true intelligent agents and delivering smarter, safer, and more trusted mobility experiences worldwide.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/reach-showcases-full-stack-product-portfolio-for-ai-vehicle-intelligent-evolution-at-auto-china-2026-302759688.html
SOURCE Reach
Technology
Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale
Published
1 hour agoon
May 1, 2026By
Achieves profitability, scales to 11,000+ platform licenses, and strengthens balance sheet with $15.7M in cash
VANCOUVER, BC and LAS VEGAS, April 30, 2026 /PRNewswire/ – Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a U.S.-focused digital health infrastructure platform, is pleased to report its audited financial results for the year ended December 31, 2025. All figures are in Canadian dollars unless otherwise stated. All references to Non-GAAP Financial Measures1 2 are as reported in the Company’s amended and restated Management Discussion and Analysis dated April 30, 2026 (“MD&A”).
Revenue reached $35.4M in 2025, with $43.6M in Adjusted Revenue1 (non-GAAP) and $2.5M in Adjusted EBITDA2 (non-GAAP), reflecting strong growth and improving operating leverage.
The Company achieved net income of $1.69M and continued to scale its platform, driven by accelerating adoption of VSDHOne and expanding transaction volumes across its national healthcare network.
FULL YEAR 2025 HIGHLIGHTS
All comparisons below are to the year ended December 31, 2024, unless otherwise noted.
Revenue: $35.4M vs. $16.04M (+121% YoY)Adjusted Revenue:(1) $43.56M vs. $22.32M (+95% YoY)Adjusted EBITDA:(2) $2.5M vs. $136K (+1,765% YoY)Rising Operating Leverage: OPEX as a % of revenue fell from 38% to 22%2025 Year-end Cash Position: $15.65M vs. $1.19M (strong balance sheet improvement)Positive Adjusted EBITDA2 across the year, reflecting improving operating leverageOver 11,000 licenses signed across the VSDHOne platform, which the Company believes demonstrates strong demand and accelerating adoption
4th QUARTER 2025 HIGHLIGHTS
All comparisons below are to the quarter ended December 31, 2024, unless otherwise noted
Revenue: $14.95M vs. $4.04M (+270% YoY)Adjusted Revenue:(1) $16.85M vs. $5.74M (+193% YoY)Adjusted EBITDA:(2) $1.58M vs. ($0.1M)Rising Operating Leverage: OPEX as a % of revenue fell to 15% in Q4 2025, versus 34% in Q4 2024
The Company believes the following Non-GAAP financial measures provide meaningful insight to its shareholders in understanding the Company’s performance and may assist in the evaluation of the Company’s business relative to that of its peers.
Notes:
(1) “Adjusted Revenue” is a non-GAAP financial measure, and the figures reflect gross economic activity processed through the Company’s platform and should not be considered revenue recognized under IFRS. See “Non-GAAP Financial Measures” section below for definition.
(2) “Adjusted EBITDA” is a non-GAAP financial measure and reflects EBITDA plus additions for atypical and non-recurring charges. See “Non-GAAP Financial Measures” section below for definition.
The following table is included to provide a reconciliation of the Company’s non-GAAP financial measures to the most directly comparable IFRS measures and to enhance the comparability and transparency of the Company’s financial performance for investors.
Three months ended December 31,
Twelve months ended December 31,
2025
2024
%
change
2025
2024
%
change
Adjusted Revenue
$ 16,853,102
$ 5,742,523
193 %
$ 43,563,753
$ 22,321,265
95 %
Deduct – deferred business partner contract
revenue
(313,878)
208,436
425,945
(45,317)
Deduct – business partner payouts on app
service gross revenue
2,218,121
1,493,509
7,752,770
6,321,866
GAAP Revenue
$ 14,948,859
$ 4,040,578
270 %
$ 35,385,038
$ 16,044,716
121 %
Adjusted Gross Margin
$ 2,924,341
$ 1,580,387
85 %
$ 9,429,151
$ 5,650,936
67 %
Deduct – deferred business partner contract
revenue
(313,878)
208,436
425,945
(45,317)
GAAP Gross Margin
$ 3,238,219
$ 1,371,951
136 %
$ 9,003,206
$ 5,696,253
58 %
Adjusted EBITDA
$ 1,577,760
$ (83,191)
$ 2,542,895
$ 136,334
1765 %
Deduct – amortization and depreciation
127,982
62,853
452,772
181,136
Deduct – share-based payments
8,843
87,889
82,385
614,877
Deduct – interest and accretion
452,209
–
586,354
–
Deduct – sales tax provision, net cash paid
252,603
(254,510)
252,603
(254,510)
Deduct – impairment charge
54,814
–
54,814
–
Deduct – income tax expense
(119,249)
–
(119,249)
–
Deduct – deferred tax recovery
699,586
–
699,586
–
GAAP Net Income (Loss)
$ 1,261,646
$ 20,577
6031 %
$ 1,694,304
$ (405,169)
518 %
Shane Madden, CEO of Hydreight, commented:
“2025 was a defining year for Hydreight. We transitioned from a growing platform into a scaled healthcare infrastructure business, with strong revenue growth and sustained profitability.
The acceleration we saw in the second half of the year was driven largely by the rollout of VSDHOne, which is now becoming a meaningful contributor to both revenue and long-term scalability.
As we move into 2026, our focus is on expanding our partner network, increasing transaction volume across the platform, and continuing to grow our compliant healthcare infrastructures in the United States.”
BUSINESS PERFORMANCE & DRIVERS
VSDHOne – Core Growth Engine
The Company’s VSDHOne platform, launched in 2025, was a primary driver of growth, contributing to:
Rapid onboarding of new partnersExpansion of direct-to-consumer healthcare brandsIncreased transaction volume across telehealth and pharmacy services
Revenue growth in 2025 was primarily driven by VSDHOne-related activity, combined with continued organic growth across existing partners.
The platform ramped significantly through the second half of the year, with Q4 alone contributing $14.9M in revenue, representing approximately 270% growth compared to the same period in 2024. This acceleration reflects strong demand from partners seeking compliant, turnkey solutions and demonstrates the Company’s ability to scale transaction volume efficiently across its infrastructure.
OPERATING METRICS & VOLUME GROWTH
Operational performance across the Company’s core verticals continued to strengthen throughout 2025.
The Company’s first two verticals continued their historical growth in 2025, supported by alignment with broader market trends and the introduction of direct-to-consumer products and services through Hydreight’s proprietary platform structure.
Completed Services revenue in Q4 2025 for the first vertical increased by approximately 44% compared to the same period in 2024Completed Services revenue for the first vertical in 2025 increased by approximately 17% compared to 2024New nurse sign-ups increased by approximately 45% in 2025 compared to 2024
These metrics reflect continued growth in the Company’s core service offerings, expansion of its provider network, and increasing utilization across the platform.
PLATFORM SCALE & NETWORK EFFECTS
Hydreight continues to expand its position as a leading healthcare infrastructure platform:
11,000+ licenses signed across VSDHOneNational footprint across all 50 U.S. statesNetwork of healthcare providers, pharmacies, and partners
The Company believes that this scale reflects growing demand from businesses seeking compliant, turnkey solutions to enter and expand within the U.S. healthcare market.
MULTI-VERTICAL REVENUE MODEL
Hydreight generates revenue across three primary streams:
Business partner subscription contractsTelehealth consultation and platform commissionsPharmacy sales
Growth was supported by:
Expansion of product offerings (GLP-1s, peptides, NAD, TRT, and more)Increased partner utilizationBroader adoption across wellness verticals
PROFITABILITY & OPERATING LEVERAGE
Hydreight achieved strong improvements in Adjusted EBITDA, a non-GAAP measure:
Adjusted EBITDA: $2.5M in 2025 vs. $0.14M in 2024 (+1,765% YoY)Net income (loss): $1.69M in 2025 vs. $(0.41)M in 2024
Performance strengthened meaningfully in the fourth quarter, reflecting the scaling of the platform in the second half of the year.
Q4 Adjusted EBITDA: $1.58M vs. ($0.10M) in Q4 2024
This reflects:
Platform scalabilityRevenue growth outpacing cost increasesImproved operational efficiency
This improvement reflects the operating leverage inherent in the Company’s platform model and was not solely a function of higher revenue. As transaction volumes scaled across VSDHOne, incremental revenue flowed through at higher margins, supported by a largely fixed regulatory, pharmacy, and technology infrastructure. As a result, revenue growth outpaced cost growth, driving improved profitability and demonstrating the scalability of the Company’s platform.
¹ See “Non-GAAP Financial Measures and Reconciliation”.
BALANCE SHEET & LIQUIDITY
Cash: $15.65M (vs. $1.2M in 2024)Working Capital: ~$15.7M (vs. deficiency of $2.5M in 2024)Strong capital position to support ongoing operations
The Company also completed a $15M financing in January 2026, subsequent to year‑end, further strengthening its ability to scale operations and pursue strategic initiatives.
Including the $15M financing completed in January 2026, the Company has access to over $30.7M in capital to support growth initiatives.
Please see SEDAR+ for the Company’s consolidated audited financial statements and MD&A for the year ended December 31, 2025.
STRATEGIC INITIATIVES & MILESTONES
Hydreight continues to expand its platform through strategic initiatives and partnerships.
During 2025, the Company:
Strengthened its vertically integrated healthcare infrastructureExpanded its national pharmacy networkInvested in next-generation platform capabilities (VSDHOne 2.0)Established strategic relationships to enhance product innovation and distribution
In 2026, Hydreight further expanded its strategic initiatives through an investment in Insu Therapeutics, a company focused on developing innovative delivery mechanisms for peptide-based therapies. This aligns with Hydreight’s long-term strategy of supporting next-generation treatments across its platform.
OUTLOOK
Hydreight is entering 2026 with strong momentum, supported by:
Continued onboarding of new partnersIncreasing transaction volumes across VSDHOneRecent capital deployment initiativesExpansion into new healthcare verticals
As of the end of Q1 2026, VSDHOne has surpassed 12,000 licenses sold, reflecting continued momentum in platform adoption.
Management remains focused on scaling the platform while maintaining disciplined growth and operational efficiency.
“We look forward to discussing these results in more detail on our upcoming earnings call.” -Shane Madden
ANNUAL FILINGS
The Company’s audited annual financial statements for the year ended December 31, 2025, and the associated MD&A, including a full discussion of non-GAAP financial measures and their reconciliation to IFRS measures, have been filed on SEDAR+ at www.sedarplus.ca and are available on the Company’s issuer profile. Readers are encouraged to review the complete financial statements and MD&A in conjunction with this press release. The Company refiled its MD&A to correct a typographical error in the calculation of Adjusted EBITDA. No other changes have been made.
UPCOMING EARNINGS CALL
Hydreight Technologies will host a live earnings call to discuss its Q4 and full-year 2025 financial results, provide a business update, and outline the Company’s strategic priorities heading into 2026.
Date & Time: Friday, May 1, 2026 at 9:00am – 10:00pm EST
Registration Link: https://hydreight.zoom.us/webinar/register/WN_vP-U6hAiRf2Ejg8muQcocQ
The call will include a formal presentation followed by a live Q&A session. Investors are encouraged to attend to gain deeper insight into Hydreight’s growth strategy and platform expansion.
Clarification on Engagement of GRA Enterprises
Further to the Company’s news release early last year dated February 27, 2025, the Company wishes to clarify that its prior 3-month engagement of GRA Enterprises LLC (doing business as National Inflation Association) (“GRA”) was not renewed and as such was terminated effective May 27, 2025.
Under the engagement, the Company paid GRA an aggregate fee of USD $30,000 in cash pursuant to the GRA Engagement. The fee was paid from general working capital at the commencement of the engagement. No securities, stock options, or other equity-based compensation were issued or granted in connection with the engagement.
The engagement was conducted at arm’s length and has been fully concluded, with no ongoing obligations or amounts payable by the Company. To the Company’s knowledge, neither GRA nor its principal, Gerard Adams, holds any direct or indirect interest in the Company or its securities, nor any right to acquire such an interest.
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Hydreight Technologies Recognized as a Top 50 TSX Venture Exchange Company
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic networks in the United States. Its proprietary, fully integrated platform has hosted a network of over 3000 nurses, over 300 doctors and a pharmacy network through its Doctor networks across 50 states. The platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking, and managing patient data, which enables licensed healthcare professionals to provide services directly to patients at home, office or hotel. Hydreight is bridging the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. The Hydreight platform allows healthcare professionals to deliver services independently, on their own terms, or to add mobile services to existing location-based operations. Hydreight has a 503B pharmacy network servicing all 50 states and is closely affiliated with a U.S. certified e-script and telemedicine provider network.
About VSDHOne – Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform is expected to help businesses launch direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy (“TRT”), hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Neither TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Use of Non-GAAP Financial Measures:
The Company uses certain non-GAAP financial measures to assess its operating performance, and this press release contains non-GAAP financial measures, including “Adjusted Revenue” and “Adjusted EBITDA”. These measures are not recognized under International Financial Reporting Standards (“IFRS”) and do not have standardized meanings prescribed by IFRS or GAAP.
The Company defines Adjusted Revenue as gross cash income before adjustment for the deferred portion of business partner contract revenue and gross receipts from Hydreight App service sales. The Company defines Adjusted Gross Margin as GAAP gross margin plus inventory impairment plus the deferred portion of business partner contract revenue. The Company defines Adjusted EBITDA as net income (loss) before interest, taxes, depreciation and amortization and before (i) transaction, restructuring, and integration costs (ii) share-based payments expense, (iii) gains/losses that are not reflective of ongoing operating performance including inventory impairment and (iv) sales tax provision, net of actual cash payments to state tax authorities.
Adjusted Revenue reflects the gross economic activity processed through the Company’s platform during the applicable period and may differ materially from revenue recognized under IFRS, which is based on revenue recognition and deferral requirements. Adjusted Revenue is not a measure of financial performance or profitability and should not be considered a substitute for revenue determined in accordance with IFRS. As used, Adjusted Revenue accelerates cash receipts relative to IFRS revenue recognition. Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS.
The Company believes that these non‑GAAP measures provide information useful to investors in understanding historical operating trends and the scale of the Company’s platform relative to its peers but does not intend for such measures to represent future performance. This data is furnished to provide additional information and does not have any standardized meaning prescribed by IFRS. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS and is not necessarily indicative of other metrics presented in accordance with IFRS.
Cautionary Note Regarding Forward-Looking Information
This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding expectations for the Company’s 2026 strategic outlook, growth, platform scaling initiatives, and anticipated expansion of VSDHOne and other platform offerings.
Forward‑looking information is based on management’s expectations, estimates and assumptions as of the date hereof, including assumptions regarding: continued partner adoption, stable regulatory regimes applicable to telehealth and pharmacy operations in the United States, availability of capital, and general economic conditions.
Investors are cautioned that forward-looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company.
Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to obtain requisite regulatory and other approvals with respect to the business operated by the Company and/or the potential impact of the listing of the Company’s shares on the TSXV on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time as a result of being a publicly listed entity. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hydreight-reports-record-fiscal-2025-results-as-vsdhone-drives-rapid-growth-and-platform-scale-302759724.html
SOURCE Hydreight Technologies Inc.
Technology
Scaled Commercial Breakthrough: OMODA & JAECOO AiMOGA Robotics Secures 1,000 Robot Orders, Boosting Smart City Deployment Step by Step
Published
1 hour agoon
May 1, 2026By
KUALA LUMPUR, Malaysia and WUHU, China, May 1, 2026 /PRNewswire/ — In response to steady advancement of smart city construction and the actual demand for efficient, low-cost urban public service equipment, OMODA & JAECOO officially launched the full-scale commercial layout of AiMOGA Robotics at the 2026 Chery International Business Summit in Wuhu. Centering on the theme “Driven by Scenarios, United for Growth”, the event witnessed a key industrial breakthrough: AiMOGA Intelligent Police Robots secured 1,000 intentional signing orders and completed an official concentrated delivery of 100 units, laying a solid foundation for orderly large-scale promotion and practical scenario operation in urban roads, traffic hubs and daily public governance links.
Jointly developed by OMODA & JAECOO and the professional AiMOGA technical team, the robotic product lineup covers humanoid robots, quadruped robots and core intelligent patrol robots. Drawing on the brand’s mature intelligent vehicle underlying technologies in perception, planning and control, the equipment retains high operational stability. It can well adapt to daily road conditions and climatic environments, independently completing core practical tasks such as real-time traffic guidance, illegal parking identification and fixed-route auxiliary patrols, effectively assisting local frontline staff and optimizing urban refined management efficiency.
Chery Group pointed out that intelligent vehicles and robots share core technological homology, and the batch signing and delivery officially means AiMOGA enters the stage of large-scale standardized commercialization. The products have been iteratively optimized in more than 100 real scenarios across 50 countries including Malaysia, with reliable performance that meets local application standards. Relying on supporting facilities such as university talent cooperation projects, 31 innovation laboratories and a special robot leasing platform launched at the conference, OMODA & JAECOO will steadily improve local supporting service capabilities. The brand will rely on its global channel advantages to accelerate the localized landing of embodied intelligent equipment, pragmatically empower the steady development of smart urban governance industry, and jointly build a complete regional intelligent service ecology with local partners.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/scaled-commercial-breakthrough-omoda–jaecoo-aimoga-robotics-secures-1-000-robot-orders-boosting-smart-city-deployment-step-by-step-302758705.html
SOURCE OMODA & JAECOO
Reach Showcases Full-Stack Product Portfolio for AI Vehicle Intelligent Evolution at Auto China 2026
Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale
Scaled Commercial Breakthrough: OMODA & JAECOO AiMOGA Robotics Secures 1,000 Robot Orders, Boosting Smart City Deployment Step by Step
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology5 days agoNeusoft Showcases Full-Stack & Global Innovations at Auto China 2026
-
Coin Market3 days agoPrice predictions 4/27: SPX, DXY, BTC, ETH, XRP, BNB, SOL, DOGE, HYPE, ADA
-
Technology5 days agoLianlian DigiTech Returns to Money20/20 Asia to Expand Partnerships, Share Industry Trends, and Explore AI-Enabled Global Financial Infrastructure
-
Coin Market5 days ago
Trump’s official memecoin extends slide as he hosts exclusive investor gala
-
Coin Market5 days ago
Ethereum Foundation unstakes 17K ETH after nearing 70K staked ETH milestone
-
Technology4 days agoGreater San Diego Science and Engineering Fair Students Win Big at the 75th California Science and Engineering Fair
-
Technology4 days agoVARON Celebrates 5 Years Supporting Easier Breathing for Customers Worldwide
-
Technology4 days agoOMODA 4 Officially Rolls Off the Production Line: OMODA&JAECOO Sets Its Sights on a New Global Million-Unit Target